Helen H. Liang, PhD

Investor and board director at Cognito Therapeutics

Helen H. Liang, PhD has a wealth of experience as an investor and board director in various companies. Helen H. is the Founder & Managing Partner of FoundersX Ventures, a venture capital firm that supports founders in the areas of enterprise SaaS, Fintech, biotech, digital health, and low-carbon industries. Additionally, Helen is an investor in Jeeves, a Fintech company that has raised significant funding and achieved unicorn status. Helen H. is also an investor in Salt Security, a leading API security solution provider, and FiscalNote, a prominent Enterprise SaaS platform for regulatory intelligence. Furthermore, Helen serves as an investor and board director of Cognito Therapeutics, Inc., a medical device company specializing in neurodegenerative disorders, and Meru Health, a digital clinic for mental healthcare. Helen has also invested in Rain Neuromorphics, Elementary Robotics, Universal Quantum, and Kernal Biologics, Inc., supporting companies in the fields of AI chip development, smart AI cameras, quantum computing, and mRNA immunotherapeutics respectively.

Helen H. Liang, PhD has a strong educational background in the field of Materials Science and Engineering. Helen H. obtained their Ph.D. from the University of Wisconsin-Madison, although the specific start year and end year for their doctoral studies are not provided.

In 2021, Helen H. Liang attended Stanford University Graduate School of Business, where they completed an Executive Program focused on exploring the paths to power, innovation, and entrepreneurship. The program likely lasted for one year, although the exact start and end dates are not mentioned.

In 2022, Helen H. Liang attended the Harvard Business School for an Executive Program on Private Equity & Venture Capital. While the duration of the program is not specified, it is likely to have been a relatively short-term program, such as a few weeks or months, rather than a full degree program. The precise start and end dates for this program are not provided.

Links

Timeline

  • Investor and board director

    June, 2022 - present